Stablix Therapeutics is pioneering a new therapeutic field of targeted protein stabilization through protein deubiquitination. Aberrant activation and expression of proteins underlies several diseases. Ubiquitin is a protein modification that is involved in protein degradation, activation and signaling. By targeting deubiquitinases (DUBs), nature’s ubiquitin editors, Stablix is establishing an adaptable platform for restoring protein stability and function. The RESTOREDTM platform generates heterobifunctional small molecules that selectively recruits active DUBs to target proteins to precisely remove ubiquitin. Currently, Stablix is leveraging their technology to treat rare diseases, cancer and immunological disorders.

Stablix Therapeutics

Drug notes:

About:

Jobs: